Literature DB >> 6351370

A monoclonal anti-pan-T-cell antibody. In vitro and in vivo studies.

P J Thurlow, E Lovering, A J d'Apice, I F McKenzie.   

Abstract

A murine monoclonal antihuman T cell antibody is described that is pan-T in that it reacts with all T cells, including those from thymus, but not with B cells or other cells, except for a small subpopulation of null cells. Biochemical analysis demonstrated that the antigen detected is a glycoprotein, Mr 50,000 daltons, in which sialic acid, alpha-fucose and alpha-mannose are the important terminal or subterminal carbohydrates. Further analysis indicated that the antigen is the E-rosette-forming-cell (ERFC) receptor or a closely associated structure. Three patients with renal allograft rejection were treated with the pan-T cell monoclonal antibody and, although the antibody was in excess and bound to circulating T cells, no lasting effect on T cell numbers or graft rejection was noted.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6351370     DOI: 10.1097/00007890-198309000-00013

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

Review 1.  The potential of biotechnology to improve the quality of life of patients with renal failure.

Authors:  W E Bloembergen; A Laupacis
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

Review 2.  Muromonab CD3. A review of its pharmacology and therapeutic potential.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

3.  Gene transfection of the HuLy-m2 (Leu-9) antigen into mouse L cells.

Authors:  M S Sandrin; K E Lovering; G Tachas; P R Collins; I F McKenzie
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

4.  Identification of CD2-/CD3+ T cells in fetal human tissue.

Authors:  D Kabelitz; P Conradt
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.